Scholars Central

EditorialPublished 2014

Patenting of Biosimilars?

Authors: Heinz Mueller

Intellectual Property Rights: Open Access

Volume 2 · Issue 4 · Pages 1–2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Patenting biosimilars before the expiration of the original patent might raise several questions for the original manufacturer as well as the biosimilar manufacturer. In general, the most eminent questions are the drafting of the original patent in a way to be protected against a wide range of similar products and for the biosimilar manufacturer to ensure that the similar product is new and inventive. Since so far no case law exists in Europe dealing with biosimilars, both manufactures are somewhat in an unclear and ambiguous situation when it comes to estimate the scope of claims of biopharmaceuticals.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Intellectual Property Rights: Open Access.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalIntellectual Property Rights: Open Access
  • SubjectBusiness & Management
  • BylineArticles whose byline prints “Heinz Mueller”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels